公司資料
Spruce Biosciences 股價、新聞與催化劑
- 股票代碼:
- SPRB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
44.77 USD (-7.84%)
收盤價
最後更新: 2026年10月1日
136M USD
市值
股價為何變動
截至 2026年10月1日，SPRB 下跌 7.84%，收於 $44.77。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Rare Neurological Disease Company
Spruce Biosciences is developing therapies for serious neurological disorders with high unmet need. Its current strategy is centered on a potential disease-modifying treatment for Sanfilippo syndrome type B.
Tralesinidase Alfa Enzyme Replacement Therapy
Tralesinidase alfa is a recombinant NAGLU enzyme replacement therapy delivered into the cerebrospinal fluid. It is designed to clear accumulated heparan sulfate from the central nervous system in children with MPS IIIB.
Long-Term Clinical Evidence
The clinical package includes years of treatment experience showing sustained biomarker normalization and preservation of cognitive, communication, and motor outcomes relative to natural-history patients. The FDA has recognized the cerebrospinal-fluid biomarker as reasonably likely to predict clinical benefit.
Accelerated-Approval Strategy
Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations support an expedited regulatory pathway. Spruce is preparing a BLA based on the integrated clinical dataset and plans a confirmatory study to support full approval.
Commercial Readiness for a Rare Disease Launch
The company is building medical, market-access, and commercial capabilities for a concentrated pediatric rare-disease population. An expanded-access program is intended to make treatment available to additional eligible patients before a potential approval.
Confirmatory Evidence Plan
Spruce plans a post-approval confirmatory study to verify clinical benefit while continuing collection of long-term natural-history and treated-patient data. This work is central to converting a potential accelerated approval into full approval.
未來催化劑
- Submission of the BLA for tralesinidase alfa in the fourth quarter of 2026.
- Initiation of the tralesinidase alfa expanded-access program in the fourth quarter of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。